tbuckley/cabot-search huggingface dataset:
Emerging agents that target signaling pathways in cancer stem cells
Authors: Yue Yang, Xiaoman Li, Ting Wang, Qianqian Guo, Tao Xi, Lufeng Zheng
Journal: Journal of Hematology & Oncology (2020)

Abstract Cancer stem cells (CSCs) contribute to the initiation, recurrence, and metastasis of cancer; however, there are still no drugs targeting CSCs in clinical application. There are several signaling pathways playing critical roles in CSC progression, such as the Wnt, Hedgehog, Notch, Hippo, and autophagy signaling pathways. Additionally, targeting the ferroptosis signaling pathway was recently shown to specifically kill CSCs. Therefore, targeting these pathways may suppress CSC progression. The structure of small-molecule drugs shows a good spatial dispersion, and its chemical properties determine its good druggability and pharmacokinetic properties. These characteristics make small-molecule drugs show a great advantage in drug development, which is increasingly popular in the market. Thus, in this review, we will summarize the current researches on the small-molecule compounds suppressing CSC progression, including inhibitors of Wnt, Notch, Hedgehog, and autophagy pathways, and activators of Hippo and ferroptosis pathways. These small-molecule compounds emphasize CSC importance in tumor progression and propose a new strategy to treat cancer in clinic via targeting CSCs.
急性心肌梗死合并心房颤动治疗的几个问题
Authors: 叶显华, 王宁夫
Journal: BMJ (2011)

吴兴田和胡秋霞医生提出的关于急性心肌梗死(心梗)合并心房颤动(房颤)治疗的几个问题很有意义,一方面代表了基层医生在临床工作中碰到的实际问题,另一方面也告诉我们基层医生需要了解什么和解决什么问题.现对所提问题回答如下。
A cross-sectional study on urgency urinary incontinence among adult women in Beijing
Authors: Jing Ge, Yong-xian Lu
Journal: BMJ (2011)

Objective To investigate prevalence and risk factors of urgency urinary incontinence (UUI) among adult women in Beijing.Methods Multiple-stage stratified sampling was used to recruit women equal to and more than 20 years old from 48 communities ( villages and neighborhoods ) in six districts of Beijing,by household interview with a standardized questionnaire to collect information of demographic characteristics,delivery history,health conditions and UUI related clinical data.Data analysis was performed by SPSS software version 16.0.Results Totally,3058 adult women completed the survey,with an overall prevalence of UUI of 1.7 % (52/3058).Distribution of age,cultural background,family income,number of pregnancy,number of abortion,delivery history,history of chronic diseases,general surgery,pelvic surgery,abdominal pain and abdominal distension were found significantly different between UUI participants and non-UUI ones with univariate analysis ( all P ＜ 0.05 ).Results of multivariate logistic regress analysis showed that number of pregnancy ( OR = 1.29,95% CI = 1.06-1.58 ),history of chronic diseases ( OR = 2.53,95% CI = 1.38-4.62 ) and history of abdominal pain ( OR = 2.32,95%CI= 1.10 -4.91 ) all significantly associated with UUI.Conclusions UUI associates with complicated factors and its prevention and intervention at communities is necessary targeting at related factors.

Key words: 
Urinary incontinence,urge; Female; Cross-sectional studies
Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study
Authors: Cheung Ka Shing, Chan Esther W, Wong Angel Y S, Chen Lijia, Wong Ian C K, Leung Wai Keung, 彭浩
Journal: BMJ (2019)

目的
质子泵抑制剂（PPIs）与胃萎缩恶化相关，尤其是在幽门螺杆菌（HP）感染者中。我们确定了在接受抗HP治疗的HP感染者中，PPIs使用与胃癌（GC）之间的相关性。


设计
本研究以中国香港全区健康资料库为基础。我们首先确认出自2003至2012年间接受过以克拉霉素为基础的三联疗法门诊处方的成年人。排除标准：使用该处方治疗失败的患者，HP治疗后12个月内确诊为GC的患者，以及治疗后发生胃溃疡者。GC排除前的6个月内开始PPIs或H2受体阻滞剂（H2RA）治疗，以避免原始偏倚。通过Cox比例风险模型的倾向分数调整，评估GC发生风险与质子泵抑制剂二者之间的关系。H2RA作为阴性对照暴露。


结果
共63 397名合格受试者入选，在平均7.6年的随访时间中，有153 (0.24%)名发生GC。PPIs使用与GC发生风险增高相关[危害比（HR）2.44, 95%可信区间（CI）1.42~4.20]，而H2RA无相关性（HR 0.72, 95% CI 0.48~1.07）。GC发生的风险随PPIs使用时间的延长而增高（PPIs使用时间≥1年、≥2年和≥3年的GC发生风险分别为：HR 5.04, 95% CI 1.23~20.61; 6.65, 1.62~27.26和8.34, 95% CI 2.02~34.41）。PPIs使用相比非PPIs使用，调整的绝对风险差为每10 000人年超过4.29 GC（95% CI 1.25~9.54）。


结论
即使在HP根除治疗后，长期使用质子泵抑制剂仍与GC的发生风险增加相关。
A real-world comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine to nab-paclitaxel in treatment of advanced stage pancreatic cancer.
Authors: Shaik Abdul Samad Shaik Abdul Rashid, Steven Cohen, Ida Micaily
Journal: Journal of Clinical Oncology (2020)

e16728 Background: Pancreatic adenocarcinoma is a dreaded malignancy accounting for 7% of all cancer related deaths in the United States. The two most used chemotherapeutic regimens are a combination of 5- fluorouracil, leucovorin, oxaliplatin and irinotecan (FFX) and a combination of gemcitabine nab paclitaxel (GN). Both improve survival when compared to gemcitabine alone but have not been compared directly. Methods: Retrospective chart review of 83 chemotherapy naïve patients with metastatic cancer of exocrine pancreas who underwent chemotherapy between February 2011 and June 2017. Patients who completed at least one cycle of chemotherapy regimen were included. Characteristics, efficacy and adverse events between the two regimens were compared using appropriate statistical analyses. Results: 83 patients met selection criteria. 39 patients received FFX and 44 received GN. Mean age of FFX and GN patients was 69.7 (SD 8.7) (Median 66) and 72.3 (SD 8.8) (Median 69) yrs respectively (p = 0.100). The proportion of patients with ECOG performance scale ≤1 receiving FFX vs. GN was 50.8% vs. 49.2% and &gt; 2 receiving FFX vs. GN was 33.3% vs 66.7% (p = .286). Of the 23 patients &gt; 75 yrs., 7 received FFX and 16 received GN (p = .086). Median overall survival was 10.1 months (95% CI: 5.4-18.7) in FFX and 7.2 months in GN (95% CI: 5.4-11.3) [p = 0.037]. Median survival based on site of tumor was 10.2 months (95% CI: 6.7-13.8) in head and 10.1 months (95% CI: 4.3-14.7) in body and tail tumors [p = 0.776]. Incidence of vomiting in FFX / GN was 94.1% / 73.7% (p =.027), vomiting requiring hospital admission was 55.9% / 21.1% (p = 0.003). Other events requiring admission included: diarrhea 31.4% / 17.9%; anemia 5.7% / 10.3%; thrombocytopenia 11.4% / 7.7%; febrile neutropenia 28.6% / 12.8% and acute kidney injury 25.7% / 15.4%; no statistically significant differences between groups. Conclusions: Patients treated with FFX had a longer survival in this retrospective review. FFX is associated with an increased incidence of vomiting requiring hospitalization. FFX remains a preferred regimen in treating patients with good performance status regardless of age.
Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure
Authors: Senthil Selvaraj, Daniel P. Kelly, Kenneth B. Margulies
Journal: Circulation (2020)

Despite existing therapy, patients with heart failure (HF) experience substantial morbidity and mortality, highlighting the urgent need to identify novel pathophysiological mechanisms and therapies, as well. Traditional models for pharmacological intervention have targeted neurohormonal axes and hemodynamic disturbances in HF. However, several studies have now highlighted the potential for ketone metabolic modulation as a promising treatment paradigm. During the pathophysiological progression of HF, the failing heart reduces fatty acid and glucose oxidation, with associated increases in ketone metabolism. Recent studies indicate that enhanced myocardial ketone use is adaptive in HF, and limited data demonstrate beneficial effects of exogenous ketone therapy in studies of animal models and humans with HF. This review will summarize current evidence supporting a salutary role for ketones in HF including (1) normal myocardial ketone use, (2) alterations in ketone metabolism in the failing heart, (3) effects of therapeutic ketosis in animals and humans with HF, and (4) the potential significance of ketosis associated with sodium-glucose cotransporter 2 inhibitors. Although a number of important questions remain regarding the use of therapeutic ketosis and mechanism of action in HF, current evidence suggests potential benefit, in particular, in HF with reduced ejection fraction, with theoretical rationale for its use in HF with preserved ejection fraction. Although it is early in its study and development, therapeutic ketosis across the spectrum of HF holds significant promise.
The management of special hypertensive patients
Authors: Ruoyi Guo, Yifang Guo
Journal: BMJ (2018)

高血压是心血管疾病最为重要的危险因素之一，降压治疗的最终目的是降低患者心血管事件风险。高血压患者的临床特征不同，其心血管系统危险水平有所不同，因此血压控制目标与降压药物选择亦有所不同。
Recent studies of obesity and asthma
Authors: 陈意, 王彤
Journal: BMJ (2011)

肥胖和支气管哮喘(哮喘)都是危害公众健康的常见慢性疾病之一,已有流行病学研究和动物实验证明两者具有关联性,近来研究的热点已开始深入至两者关联机制的基础性研究和对肥胖性哮喘患者的临床治疗上.本文就肥胖与哮喘相关性的基础和临床研究进展做综述.
全厚皮片移植治疗儿童颈部瘢痕挛缩畸形14例
Authors: 姜文荃
Journal: BMJ (2005)

我院自2001年5月至2003年7月共治疗儿童颈部瘢痕挛缩畸形14例,疗效较好,现报告如下. 1.对象与方法:男10例,女4例;年龄3～11岁,平均(7±3)岁.致伤原因:烧烫伤11例,化学烧伤2例,电烧伤1例.瘢痕形成时间:0.5～3年.瘢痕范围:最小下至颈部一侧锁骨上缘,上至耳垂后发际,前至同侧口角垂直线,后至颈侧正中线;最大下至乳头水平,上至枕骨,前后成不全环状.按颌颈部瘢痕分度法[1]:Ⅱ型4例,Ⅲ型6例,Ⅳ型3例,Ⅴ型1例。
Overall survival after <sup>177</sup>Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial.
Authors: Jeremie Calais, Jeannine Gartmann, Wesley R Armstrong, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa, Roger Slavik, Magnus Dahlbom, Ken Herrmann, Matthias Eiber, Wolfgang Peter Fendler, Johannes Czernin
Journal: Journal of Clinical Oncology (2020)

5549 Background: This was an open-label randomized prospective bi-centric single-arm phase II clinical trial of 177 Lu-PSMA-617 molecular radiotherapy in patients with progressive metastatic castrate-resistant prostate cancer (mCRPC) conducted at University of California Los Angeles (USA) and Excel Diagnostics &amp; Nuclear Oncology Center (Houston, TX, USA) (NCT03042312). The study was investigator-initiated under an investigational new drug approval protocol (IND#133661) with authorization of charging for investigational drug (cost-recovery, Title 21 CFR 312.8). We report here the post-hoc analysis of overall survival (OS) in a single-study site cohort (UCLA). Methods: Patients with progressive mCRPC (biochemical, radiographic, or clinical) after ≥1 novel androgen axis drug (NAAD), either chemotherapy (CTX) naïve or post-CTX, with sufficient bone marrow reserve, normal kidney function, and sufficient PSMA-target expression by PET were eligible. Patients received up to 4 cycles of 177 Lu-PSMA-617 every 8±1 weeks and were randomized into 2 treatment activities groups (6.0 or 7.4 GBq). Efficacy was defined as serum PSA decline of ≥50% from baseline and served as primary endpoint (hypothesis: ≥40% of responders after 2 cycles). Results: 43 patients were randomized to the 6.0 GBq (n= 14) and 7.4 GBq (n=29) treatment arms. 11/43 (26%) were CTX naïve while 10/43 (23%), 12/43 (28%), 5/43 (12%) and 5/43 (12%) had received 1, 2, 3 or 4 CTX regimens. Median baseline PSA was 29.2 ng/ml (mean 228.8, range 0.5-2082.6). 21/43 (49%) completed 4 cycles of 177 Lu-PSMA-617 whereas 4/43 (9%), 13/43 (30%) and 5/43 (12%) underwent 1, 2 and 3 cycles. PSA decline of ≥50% was observed in 11/43 of patients (26%) after 2 cycles and in 16/43 (37%) at any time (best PSA response). 9/43 (21%) had a PSA decline of ≥90% and 23/43 (53%) had any PSA decline (&gt;0%). After a median follow-up of 19.5 months the median OS was 14.8, 15.7 and 13.5 months in the whole cohort, the 6.0 GBq and 7.4 GBq treatment arms, respectively (p=0.68). Patients showing a PSA decline of ≥50% after 2 cycles and at any time had a longer OS: median 20.1 months vs. 13.6 (p=0.091) and 20.1 vs. 11.6 (p=0.002), respectively. Conclusions: In this post-hoc analysis of a single-site cohort of 43 patients included in a prospective phase II trial the median OS after 177Lu-PSMA-617 molecular radiotherapy in patients with progressive mCRPC was 14.8 months. There was no difference of efficacy between the 6.0 GBq and 7.4 GBq treatment arms. Clinical trial information: NCT03042312 .
Characterization of the tumor microenvironment landscape and deep learning-guided prediction of prognosis in lung adenocarcinoma with bulk RNA sequencing data.
Authors: Philippe Gui, Wei Wu, Elizabeth Yu, Caroline Elizabeth McCoach, Robert Charles Doebele, Trever G. Bivona
Journal: Journal of Clinical Oncology (2020)

e21025 Background: The tumor microenvironment (TME) plays an important role in tumor progression and treatment response, therefore profoundly affecting patient outcomes. Efforts to characterize the TME in lung adenocarcinoma are emerging but have been limited by the sample size and lack of treatment timepoints. Methods: We characterized changes in lung TME using the xCell algorithm to distinguish 64 immune and stroma cell types from bulk RNA sequencing data. The correlation between subtype cell population in lung TME and various clinical and biological characteristics was analyzed from over 500 lung adenocarcinoma (LUAD) samples from The Cancer Genome Atlas and an independent cohort of 48 advanced LUAD patients with treatment annotations (treatment-naive, residual disease, and progressive disease). In addition, we used key features in lung TME to predict prognosis using deep learning algorithms. Results: We found significant changes in both immune and stroma cell populations according to various clinical parameters such as smoking history, cancer stage, and treatment status. Specific sub-populations within lung TME correlate with survival outcomes based on Kaplan-Meier survival analyses. CD4- and CD8-positive T-cells are enriched in early stage disease and depleted in late stage disease, suggesting evolution of the TME during cancer progression. Consistent with previous reports, scores of immune cell populations associated with worse survival, such as T helper type 2 cells, are increased in late stage disease. Smoking history also reshapes the lung TME as populations correlated with better survival are decreased in smokers. We also found variations in sub-populations according to the driver oncogenes, with a less abundant lymphoid compartment in EGFR mutant samples compared to KRAS driven samples. Interestingly, we found higher scores of macrophage populations in residual disease following targeted-therapy treatment compared to pre-treatment. Finally, using machine and deep learning methods we identified a panel of 12 key features within the lung TME which could be used to predict prognosis. Conclusions: We comprehensively characterized immune and stroma cell type changes in the lung TME utilizing bulk RNA-seq data, and evaluated the association of sub-type cell populations with different clinical and biological features. Key features in lung TME could be used to predict prognosis.
尿液甘氨酰脯氨酸二肽氨基肽酶测定对高血压患者肾脏早期损害的诊断价值
Authors: 李振华, 王丽华, 杨文东
Journal: BMJ (2004)

我们检测和比较常规尿检阴性的高血压病患者尿液的甘氨酰脯氨酸二肽氨基肽酶(GPDA)、微量白蛋白(mALB)、视黄醇结合蛋白(RBP),以探讨尿液GPDA在高血压患者肾脏早期损害诊断中的价值。
Therapeutic value of early bronchoscopy in aspiration pneumonia patients after nasopharyngeal carcinoma radiotherapy
Authors: Bing Liu, Jiong Yang, Yan-qing Ye, Zhen-shun Cheng, Kai-song Wu, Wei-wei Dong
Journal: BMJ (2012)

A total of 41 patients with aspiration pneumonia after nasopharyngeal carcinoma radiotherapy were retrospectively selected from January 2005 to December 2010.They were divided into early bronchoscopy group (n =24) and conventional therapy group (n =17) to analyze the therapeutic effects of early bronchoscopy on temperature,white blood cell (WBC),absorption of chest radiography and mortality rates.The temperature and WBC were at the same level between both groups at pre-treatment [(38.7 ±0.7)℃ vs.(38.5 ±0.7)℃,P=0.633; (15.8 ±4.2) × 109/L vs.(16.2 ±3.4) × 109/L,P =0.430]while the temperature declined obviously after a 3-day treatment [(37.3 ±0.9)℃ vs.(38.4 ± 1.4)℃,P =0.015] and also WBC after a 5-day treatment[(10.6±4.2) × 109/L vs.(15.3 ±6.9) × 109/L,P=0.045].The bronchoscopy group had a faster absorption of chest radiography (Z =-3.515,P =0.00).The mortality rate showed no statistically significant difference between both groups.

Key words: 
Pneumonia, aspiration; Bronchoscopes
The common influential factors of hypertension caused by medicine
Authors: 常桂娟, 李南方
Journal: BMJ (2007)

药物性高血压是指在临床工作中,使用常规药物剂量治病时,由于药物本身作用或该药物与其他药物之间发生相互作用而引起血压升高,当血压超过140/90 mm Hg(1 mm Hg=0.133 kPa)时即考虑药物性高血压.在高血压病因分类中,药物性高血压属于继发性高血压。
Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
Authors: Henry Jacob Conter, Neal D. Shore, William R. Berry, Peter C.C. Fong, Jose Maria M. Piulats Rodriguez, Leonard Joseph Appleman, Tilman Todenhöfer, Gwenaelle Gravis, Brigitte Laguerre, Howard Gurney, Margitta Retz, Emanuela Romano, Loic Mourey, Johann S. De Bono, Audrey E. Kam, Urban Emmenegger, Haiyan Wu, Ping Qiu, Charles Schloss, Evan Y. Yu
Journal: Journal of Clinical Oncology (2020)

5545 Background: Pembro + enza (cohort C) has shown antitumor activity and acceptable safety in abi-pretreated pts with mCRPC in the phase I/II KEYNOTE-365 study (NCT02861573). Updated results with new biomarker data from cohort C are reported. Methods: Pts who became intolerant to or for whom ≥4 weeks of abi failed in the prechemotherapy mCRPC state and who progressed within 6 mo of screening were enrolled. Pts received pembro 200 mg IV Q3W + enza 160 mg/day orally. Primary end points were PSA response rate (PSA decrease ≥50%; confirmed by a second value ≥3 weeks later), ORR per RECIST v1.1 by blinded independent central review, and safety. Key secondary end points were DCR per RECIST v1.1 (CR+PR+SD or non-CR/non-PD ≥6 mo), DOR per RECIST v1.1, radiographic PFS (rPFS) per PCWG-modified RECIST v1.1, and OS. Biospecimens (eg, blood, tissue) were collected at baseline and during the study for biomarker analysis, including tissue PD-L1 expression, androgen receptor variant 7 (AR-v7) expression in circulating tumor cells (CTCs), and a T-cell-inflamed gene expression profile (GEP). Results: Of 103 enrolled pts, 102 were treated; 39% of treated pts had measurable disease. Median (range) time from enrollment to data cutoff was 19.1 mo (1.1-28.8) for all pts and 21.4 mo (15.1-28.8) for pts with ≥27 wks’ follow-up (n=69). Confirmed PSA response rate was 22% in 101 pts with a baseline PSA assessment. Median time to PSA progression was 3.5 mo (95% CI, 2.9-4.0). In pts with measurable disease and ≥27 wks’ follow-up (n=25), confirmed ORR was 12% (2 CRs, 1 PR) and DCR was 32%. Median DOR was not reached (range, 0.0+ to 24.4+ mo); 2 pts had a response for ≥6 mo. In all pts, median (95% CI) rPFS was 6.1 mo (4.4-6.5) and median OS was 20.4 mo (15.5-NR). At 6 mo, rPFS rate was 55.1% and OS rate was 88.2%. Treatment-related AEs occurred in 92 pts (90%); most frequent (≥20%) were fatigue (38%), nausea (22%), and rash (20%). Grade 3-5 treatment-related AEs occurred in 40 pts (39%). Three pts died of AEs (1 AE was treatment related [cause unknown]). Of all pts, 29% had PD-L1 + tumors (combined positive score ≥1). Of 51 pts with AR-v7 data, 13.7% were AR-v7 + and 86.3% were AR-v7 − . GEP was not significantly associated with ORR or PSA response. Conclusions: Pembro + enza continued to show activity in pts with abi-pretreated mCRPC. Safety of the combination was consistent with the known profiles of pembro and enza. A phase III study of this combination is ongoing (KEYNOTE-641, NCT03834493). Clinical trial information: NCT02861573 .
Status of outpatient service for cancer patients in Beijing Yuetan Community Health Service Center
Authors: Yan Ji, Xue Chen
Journal: BMJ (2019)

Objective
To analyze the outpatient service for patients with malignancies in Yuetan Community Health Service Center of Xicheng District in Beijing.


Methods
Two hundred and nine patients with malignancies visiting Yuetan Community Health Service Center in Beijing from January 2016 to January 2018 were included for analysis. There were 92 patients who visited fixed physicians (fixed group) and 117 patients who visited non-fixed physician (non-fixed group), and the influencing factors affecting fixed physician visit were analyzed.


Results
Of the 209 patients, 65 (31.10%) were males and 144 (68.90%) were females with a mean age of (69.4±10.0) year. There were 114 cases (54.55%) complicated with, hypertension 52 cases (24.88%) complicated with type 2 diabetes and 40 cases (19.24%) complicated with dyslipidemia. The mean number of visit per patients was (23.16±3.86) times; and the time of visits in fixed group was significantly higher than that in non-fixed group [(27.72±2.67) vs. (22.93±2.61), χ2=4.621, P=0.01]. The mean number of visit in 107 patients having contracted family doctor service was (25.64±7.60) times, while the time of visits in fixed group was significantly higher than that of the non-fixed group [(32.10±2.10) vs. (13.56±3.34), χ2=3.938, P<0.01]. Multivariate logistic regression analysis showed that hypertension (OR=0.445, 95%CI:0.213-0.971) and contracted family doctor service (OR=0.212, 95%CI:0.104~0.435) were significantly associated with fixed physician visits.


Conclusion
The outpatient visits of patients with malignant tumors in Yuetan Community Health Service Center meet the follow-up requirements for chronic diseases in the National Basic Public Health Service Regulations. The number of visits to fixed physicians is high, and patients with hypertension and contracted family doctor service have higher rate of fixed physician visits.


Key words: 
Malignancies; Ambulatory care; Family doctor service
Diagnosis and treatment of primary omental torsion: an analysis of 12 cases
Authors: Xiaowei He, Shidai Shi
Journal: BMJ (2017)

Objective
To analyze the clinical features, diagnosis and treatment of the primary omental torsion (POT).


Method
The clinical data of 12 patients with POT admitted to our hospital from May 2010 to May 2015 were retrospectively reviewed. The clinical manifestations, laboratory investigation, medical image, treatment and outcomes of patients were analyzed.


Results
Twelve cases were all males with median age of 50. The POT was diagnosed during surgical exploration and confirmed pathologically after operation. Right abdominal pain was the main complaint in 11 cases, and pain migration to right lower quadrant in 1 case. In physical examination, the local peritonitis signs were elicited, including right quadrant tenderness and rebound tenderness at same location. All cases had normal temperature except one presenting low fever of 37.5 ℃. White blood cell counts was 12×109/L in one case, and( 4-10)×109/L in other 11 cases. Abdominal solid mass was found in one case by ultrasonic scan, measured 7 cm×5 cm with unclear surrounding boundary. Mesenteric fat opacity and dropsy were shown in 10 cases on CT plain scan, while thickness and effusion of hepatic flexure of colon was found in one case; however, none of them were suggested as POT by these two image study before operation. All patients were diagnosed as localized peritonitis or appendicitis clinically before emergent surgical exploration. The necrotic omentum was resected and all patients recovered smoothly. There were no complications in all cases during one-year follow-up. The CT images were reviewed after operation, which indicated that the mesentery of dropsy and the thickened hepatic flexure of colon should be the imaging signs of omental torsion; and also 9 of 12 cases had whirlpools sign.


Conclusion
The preoperative diagnosis of POT is difficulty, the typical whirlpools sign of abdominal mass on CT imaging is of highly value in diagnosis. The surgical removal of omental infarction is effective and the prognosis is good.


Key words: 
Torsion, omentum; Fat necrosis; Diagnosis; Therapy